Surface modified and rituximab functionalized PAMAM G4 nanoparticle for targeted imatinib delivery to leukemia cells: In vitro studies

Fotouhi, Parastoo; Sohrabi, Saeedeh; Nosrati, Negar; Vaziri, Ali; Khaleghi, Sepideh; Narmani, Asghar; Jafari, Hanieh; Mohammadnejad, Javad

doi:10.1016/j.procbio.2021.09.006

Cited by 29 publications

(9 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To solve this problem, the use of nanotechnological strategies has been proposed to improve the bioavailability and efficacy of curcumin 58 . Nanomaterials‐based therapeutic delivery has been presented a remarkable potency for overcoming the shortcoming of curcumin and improving its appropriate aspects such as increasing high solubility, good pharmacokinetics and pharmacodynamics, biodegradability, the good surface to volume ratio, suitable serum stability by avoiding probable reaction of the immune system due to its nano‐size, biocompatibility, good physicochemical aspects, and so forth 75–77 . Moreover, to further enhancement in the above‐mentioned features of nano‐size materials, such as nano‐curcumin, using adjuvants, stabilizers, conjugates/polymer conjugates, nanogels, and nanoparticles could be useful somehow.…”

Section: Discussionmentioning

confidence: 99%

The cardioprotective effects of nano‐curcumin against doxorubicin‐induced cardiotoxicity: A systematic review

et al. 2022

Self Cite

View full text Add to dashboard Cite

Although the chemotherapeutic drug, doxorubicin, is commonly used to treat various malignant tumors, its clinical use is restricted because of its toxicity especially cardiotoxicity. The use of curcumin may alleviate some of the doxorubicin‐induced cardiotoxic effects. Especially, using the nano‐formulation of curcumin can overcome the poor bioavailability of curcumin and enhance its physicochemical properties regarding its efficacy. In this study, we systematically reviewed the potential cardioprotective effects of nano‐curcumin against the doxorubicin‐induced cardiotoxicity. A systematic search was accomplished based on Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines for the identification of all relevant articles on “the role of nano‐curcumin on doxorubicin‐induced cardiotoxicity” in the electronic databases of Scopus, PubMed, and Web of Science up to July 2021. One hundred and sixty‐nine articles were screened following a predefined set of inclusion and exclusion criteria. Ten eligible scientific papers were finally included in the present systematic review. The administration of doxorubicin reduced the body and heart weights of mice/rats compared to the control groups. In contrast, the combined treatment of doxorubicin and nano‐curcumin increased the body and heart weights of animals compared with the doxorubicin‐treated groups alone. Furthermore, doxorubicin could significantly induce the biochemical and histological changes in the cardiac tissue; however, coadministration of nano‐curcumin formulation demonstrated a pattern opposite to the doxorubicin‐induced changes. The coadministration of nano‐curcumin alleviates the doxorubicin‐induced cardiotoxicity through various mechanisms including antioxidant, anti‐inflammatory, and antiapoptotic effects. Also, the cardioprotective effect of nano‐curcumin formulation against doxorubicin‐induced cardiotoxicity was higher than free curcumin.

show abstract

Section: Discussionmentioning

confidence: 99%

The cardioprotective effects of nano‐curcumin against doxorubicin‐induced cardiotoxicity: A systematic review

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…To figure out the internalization efficiency of internalized FA‐PLGA‐Alg nanocarrier in HepG2 cells, the flow cytometry approach was employed [11]. This test was done after 5 h of incubation in cancer cells.…”

Section: Methodsmentioning

confidence: 99%

“…The flow cytometry technique was carried out to evaluate the apoptosis-inducing capability of nanocarriers in the HepG2 cancer cell line after 24 h of treatment with the IC 50 concentrations. This test is based on the annexin V-FITC/propidium iodide (PI) staining procedure as the following procedure [11]. Approximately, 2 × 10 5 cells/mL of HepG2 cells were spilled in each well of a six-well plate and incubated at 37 • C and 5% CO 2 overnight.…”

Section: Apoptosis Assaymentioning

confidence: 99%

“…On the other hand, although conventional approaches, including surgery, chemotherapy, radiotherapy, thermal therapy, etc., have been developed and applied for the treatment of cancer, the drawbacks and limitations of these modalities have not resulted in its suppression [11]. These restrictions of conventional approaches are including toxicity, organ amputation, few specificities, long-term period of treatment, injury, multi-drug resistance, side effects, high repetition, low stability in serum, immune response, and high cost of treatment which have made these approaches inefficient [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biopolymer‐based nanoparticles as promising candidate for inducing apoptosis in liver cancer cells

Hoseinzadeh,

Mokhtari,

Kafilzadeh

et al. 2023

Micro & Nano Letters

Self Cite

View full text Add to dashboard Cite

Liver cancer is one of the most common causes of death all around the globe. On the other hand, conventional modalities, such as chemotherapy and surgery, have not been effectively suppressed cancer incidence due to some deficiencies. As a result, a novel folic acid (FA)‐decorated poly lactic‐co‐glycolic acid (PLGA)‐Alginate (Alg) nanocarrier was efficiently developed for active doxorubicin (Dox) delivery to human HepG2 liver cancer cells. The in vitro assays, including cell viability assay (MTT (3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide) test), apoptosis, cell cycle arrest, and cellular uptake, were applied to evaluate the cancer cell growth suppression and apoptosis‐inducing ability of the nanocarrier. More than 85% cytotoxicity was attained after 24 h of treatment with 400‐nM concentration of FA‐PLGA‐Dox‐Alg. More than 21% and 61% apoptosis were observed after 24 h of treatment with 100‐nM concentrations of FA‐PLGA‐Dox‐Alg in apoptosis and cell cycle arrest assays. The cellular uptake of the FA‐PLGA‐Alg nanocarrier was about 30% higher than that of the PLGA‐Alg carrier which indicated the cancer cell targeting ability of the FA‐PLGA‐Alg sample. These results have indicated the potential capability of FA‐PLGA‐Dox‐Alg in the inhibition of liver cancer cells.

show abstract

“…on their compartments. FA, as a kind of vitamin with a molecular weight of 441 Da, can bind to folic acid receptors (FR) with high affinity on the membrane of cancer cells [24]. While FR overexpresses on the surface of many malignant cancer cells, like liver, lung, breast, colon cancers etc., it has restricted expression on the normal cells of the human which exponentially increases the possibility of internalisation of FA-decorated nanocarriers in cancer cells [25,26].…”

Section: Introductionmentioning

confidence: 99%

Poly lactic‐co‐glycolic acid‐alginate nanocarrier for efficient drug delivery to liver cancer cells

Hoseinzadeh

Mokhtari

Kafilzadeh

et al. 2023

IET Nanobiotechnology

Self Cite

View full text Add to dashboard Cite

Efficient drug delivery systems (DDSs) can potentially replace with conventional modalities in cancer therapy, like liver cancer. In this study, a novel folic acid (FA)‐functionalised and alginate (Alg)‐modified poly lactic‐co‐glycolic acid (PLGA) nanocomposite was developed for delivery of doxorubicin (Dox) to HepG2 and Huh7 liver cancer cells. After synthesising the nanocarrier, several analytical devices, including FT‐IR, DLS, TGA, and TEM, were employed for its characterisation. Nano‐metric size (55 and 85 nm in diameter), close to neutral surface charge, semi‐spherical morphology, and successful synthesis were approved. Dox entrapment efficiency was determined near 1%, and sustained and pH‐sensitive drug release behaviours of nanocarrier were ascertained for DDS. Afterwards, the cell viability test was carried out to study the HepG2 and Huh7 cells suppression capability of FA‐PLGA‐Dox‐Alg. About 12% and 10% cell viabilities were observed in HepG2 and Huh7 cancer cells after 24 h treatment with 400 nM concentration of FA‐PLGA‐Dox‐Alg nanocarrier respectively. The IC50 value was observed for 100 nM after 24 h of treatment in cancer cells. These data have indicated that fabricated nanocarrier could be promising DDS against liver cancer and replace with conventional approaches in cancer treatment, like chemotherapy.

show abstract

Surface modified and rituximab functionalized PAMAM G4 nanoparticle for targeted imatinib delivery to leukemia cells: In vitro studies

Cited by 29 publications

References 43 publications

The cardioprotective effects of nano‐curcumin against doxorubicin‐induced cardiotoxicity: A systematic review

The cardioprotective effects of nano‐curcumin against doxorubicin‐induced cardiotoxicity: A systematic review

Biopolymer‐based nanoparticles as promising candidate for inducing apoptosis in liver cancer cells

Poly lactic‐co‐glycolic acid‐alginate nanocarrier for efficient drug delivery to liver cancer cells

Contact Info

Product

Resources

About